• Reversine and Aurora Kinase Inhibition: Redefining Mitotic C

  2026-05-22

  Explore how Reversine, a potent Aurora kinase inhibitor, uniquely enables advanced dissection of mitotic checkpoint disassembly and cell cycle regulation in cancer research. This article offers an in-depth mechanistic analysis, bridging recent biochemical insights with practical assay strategies for oncology studies.

• EZ Cap™ Cas9 mRNA (m1Ψ): Optimizing Genome Editing Precision

  2026-05-21

  EZ Cap™ Cas9 mRNA (m1Ψ) sets a new standard for CRISPR-Cas9 genome editing, offering superior mRNA stability, translation efficiency, and minimized immune activation. This guide delivers actionable protocols, advanced troubleshooting, and insights from recent research to help researchers achieve high-fidelity genome modifications in mammalian systems.

• Thioguanine and Epigenetic Modulation: A Paradigm in Cancer

  2026-05-21

  Explore how Thioguanine, a potent thiopurine immunosuppressant, uniquely targets epigenetic regulation in cancer and antiviral research. This article reveals advanced mechanistic insights and assay strategies distinct from standard protocol guides.

• Cediranib (AZD2171): Potent VEGFR Inhibitor for Angiogenesis

  2026-05-20

  Cediranib (AZD2171) is a highly potent, ATP-competitive tyrosine kinase inhibitor targeting VEGFR family members. It shows sub-nanomolar efficacy in inhibiting VEGFR-2 and supports advanced angiogenesis and cancer research. Its mechanism and benchmarks are well-documented and suitable for robust in vitro assay integration.

• T7 RNA Polymerase: Accelerating RNA Therapies in Oncology

  2026-05-20

  This thought-leadership article examines how mechanistic and workflow insights into T7 RNA Polymerase can strategically empower translational researchers developing next-generation RNA therapeutics, particularly in the context of lung cancer immunotherapy. By integrating recent mechanistic findings, benchmarking APExBIO’s recombinant enzyme, and outlining experimental and clinical implications, the piece bridges foundational molecular biology with visionary therapeutic applications, offering advanced guidance and practical protocol parameters.

• DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe: Pr

  2026-05-19

  DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe is a robust tool for labeling plasma membranes, enabling reliable visualization in live and fixed cell preparations. It is best suited for neuronal tracing, cell migration, and membrane-specific analysis, but is not appropriate for aqueous staining or workflows that disrupt membrane integrity.

• Technical Guidance for Angiotensin I/II (1-5) in RAS Researc

  2026-05-19

  Angiotensin I/II (1-5) provides researchers with a defined Asp-Arg-Val-Tyr-Ile peptide fragment for modeling blood pressure regulation and aldosterone signaling in cardiovascular and renal workflows. This product is not suitable for studies outside the renin-angiotensin system or unrelated peptide signaling pathways due to specific solubility and storage requirements.

• Patient-Derived Gastric Cancer Assembloids Reveal Tumor–Stro

  2026-05-18

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids with stromal cell subpopulations, more accurately recapitulating the tumor microenvironment. The model reveals how stromal components modulate gene expression and drug response, enhancing the physiological relevance of preclinical drug screening and informing personalized therapy strategies.

• ALDOB K87 Lactylation Orchestrates Mitochondrial Fission in

  2026-05-18

  Yi et al. (2026) reveal that ALDOB K87 lactylation is a critical driver of mitochondrial fission and metabolic reprogramming in pulmonary hypertension (PH). By decoding the lactate–ALDOB–DRP1 axis in pulmonary artery smooth muscle cells, the study uncovers new molecular mechanisms underlying vascular remodeling and identifies potential intervention points for PH.

• KX2-391 Dihydrochloride: Precision Tools for Oncology & Viro

  2026-05-17

  KX2-391 dihydrochloride (Tirbanibulin dihydrochloride) stands out as a dual Src kinase and tubulin inhibitor with unique multi-pathway coverage, enabling high-specificity interventions across cancer and viral research. This guide details advanced workflows, troubleshooting insights, and key lessons from translational metastasis research, empowering users to optimize experimental design and reproducibility.

• Quinolone–Coumarin Hybrids Show Potent Anti-Toxoplasma Activ

  2026-05-16

  The referenced study introduces quinolone–coumarin hybrids, derived from fluoroquinolones and novobiocin, as promising anti-parasitic agents with high selectivity against Toxoplasma gondii. These findings open new avenues for developing safer, more effective treatments for toxoplasmosis, especially for immunocompromised individuals.

• Pioglitazone: Selective PPARγ Agonist for Metabolic Disorder

  2026-05-15

  Pioglitazone is a potent, selective PPARγ agonist widely used in metabolic disorder research, including type 2 diabetes mellitus and inflammatory models. Its ability to modulate macrophage polarization and STAT signaling is verifiable in both cellular and animal systems. This article presents atomic, evidence-backed insights into pioglitazone’s mechanism, benchmarks, and workflow integration.

• AO/PI Double Staining Kit: Reliable Cell Viability & Death D

  2026-05-15

  The AO/PI Double Staining Kit offers a rapid, direct method to distinguish viable, apoptotic, and necrotic cells in heterogeneous populations, addressing the challenge of accurate cell viability and death discrimination in research workflows. It is best suited for fluorescence-based assays in cell biology where clear discrimination among these cell states is required; it is not intended for non-fluorescent or in vivo imaging applications.

• Cyclophilin A Loss Confers Cyclosporine Resistance in Mice

  2026-05-14

  This study demonstrates that cyclophilin A is essential for cyclosporine-mediated immunosuppression, with Ppia−/− mice showing resistance to the drug. These findings clarify the molecular mechanism of selective calcineurin inhibition and have direct implications for designing and interpreting immune response suppression protocols in transplantation immunology research.

• JZL184: Applied Protocols for Monoacylglycerol Lipase Inhibi

  2026-05-14

  JZL184 unlocks precise endocannabinoid system modulation, making it a go-to monoacylglycerol lipase inhibitor for pain and neuropharmacology research. Explore detailed workflows, troubleshooting insights, and translational use-cases that set JZL184 apart for both in vitro and in vivo studies.

11142 records 2/743 page Previous Next 12345 下5页 Last page